An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin

NCT00274443 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: ABI-007 (Abraxane) and Carboplatin

Sponsor

Celgene